Stage-Dependent Role of Eicosanoids in Colorectal Cancer

Q: What are the key findings of this study?

Elevated serum TXB2 was associated with higher odds of advanced TNM stage ≥ III (adjusted OR 1.560, 95% CI 1.125–2.165; p = 0.008) in patients with colorectal cancer.

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Colorectal cancer (n=122). Intervention: Serum eicosanoid levels (TXB2, per 8.535-unit IQR increase) vs. Lower TNM stage (TNM < III). Primary outcome: Advanced TNM stage (TNM ≥ III) in adjusted stepwise logistic model (OR 1.560, 95% CI 1.125-2.165, p=0.008).

Jakub Klekowski; Paulina Fortuna; Mariusz Chabowski; Łukasz Lewandowski; Wioleta Szewczak; Karolina Mosna; Gabriela Maciejewska; Marek Zawadzki; Małgorzata Krzystek-Korpacka; Mariusz G. Fleszar

doi:10.3390/ijms27041641

February 8, 2026Open Access

Stage-Dependent Role of Eicosanoids in Colorectal Cancer

View Full Paper

Ask AI

Bookmark

Share

Key result

Elevated serum TXB2 linked to ~56% higher odds of advanced colorectal cancer.

OR 1.560
95% CI 1.125-2.165
P=0.008
n=122

Key Points

To evaluate the stage-dependent role of serum eicosanoids as circulating biomarkers in patients undergoing curative resection for colorectal cancer.
Prospective cohort study of 122 patients undergoing curative colorectal resection, stratified into TNM stage < III (n = 66) versus TNM ≥ III (n = 56).
Serum eicosanoid profiles were quantified using targeted metabolomics and evaluated with penalized and likelihood-based stepwise regression models adjusting for age and gender.
Serum concentrations of PGD2 (p = 0.008), PGE2 (p = 0.006), and TXB2 (p = 0.008) were significantly higher in patients with TNM ≥ III compared to TNM < III.
Stepwise logistic regression identified elevated TXB2 as independently associated with advanced TNM stage (adjusted OR = 1.560; 95% CI 1.125–2.165; p = 0.008) and lymph node invasion (adjusted OR = 1.358; 95% CI 1.057–1.748; p = 0.017).
In penalized modeling of local T-stage invasion, higher LTB4 associated with lower odds of advanced T-stage (OR = 0.481; 95% CI 0.292–0.794; p = 0.004), while higher PGD2 linked to increased odds of higher T-stage (OR = 1.876; 95% CI 1.096–3.205; p = 0.022).

Study Design

Type

Cohort (n=122)

Multicenter

No

PICO

P

Population

122 adult patients with stage I–IV colorectal cancer undergoing elective curative colorectal resection at a single center in Poland.

E

Exposure / Comparator

Serum eicosanoid levels (TXB2, per 8.535-unit IQR increase) vs Lower TNM stage (TNM < III)

O

Primary Outcome

Advanced TNM stage (TNM ≥ III) in adjusted stepwise logistic model — OR 1.560 (1.125-2.165), p=0.008

Main Result

Odds Ratio: 1.56 (95% CI 1.125–2.165)

p-value: p=0.008

Limitations

Absence of a healthy control group
Incomplete clinicopathological and molecular data (such as KRAS, NRAS, BRAF, or MSI) available for only a fraction of individuals
Lack of post-operative serum analysis and long-term follow-up
Limited sample size and events-per-variable ratio potentially limiting the stability of feature selection
Lack of tissue sample comparisons

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Evaluating eicosanoid levels in colorectal cancer patients, indicating disease stage progression.

Abstract

Colorectal cancer (CRC) is a major health concern with increasing incidence, especially in younger adults. This study evaluated the stage-dependent role of serum eicosanoids as biomarkers in CRC patients. A cohort of 122 patients undergoing curative colorectal resection was prospectively recruited. Serum eicosanoid profiles were evaluated using targeted metabolomics and analyzed through regression-based statistical models to identify associations with CRC staging. The more advanced stages of CRC (with N+ and M+) showed significantly increased levels of PGD2, PGE2, and TXB2. The latter proved to be consistently associated with advanced disease. LTB4 and PGD2 showed inverse relationships relative to each other with respect to local invasion, showing PGD2 as a marker of higher T stages. PGE2 was not recognized as a viable biomarker. The progression of CRC is associated with distinct alterations in eicosanoid profiles. This study showed the potential of TXB2, LTB4, and PGD2 as indicators of CRC advancement.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Klekowski et al. (2026) conducted a cohort in Colorectal cancer (n=122). Serum eicosanoid levels (TXB2, per 8.535-unit IQR increase) vs. Lower TNM stage (TNM < III) was evaluated on Advanced TNM stage (TNM ≥ III) in adjusted stepwise logistic model (OR 1.560, 95% CI 1.125-2.165, p=0.008). Elevated serum TXB2 was associated with higher odds of advanced TNM stage ≥ III (adjusted OR 1.560, 95% CI 1.125–2.165; p = 0.008) in patients with colorectal cancer.

synapsesocial.com/papers/698acad77c832249c30ba582 https://doi.org/10.3390/ijms27041641

View Full Paper

Ask AI

Bookmark

Share

Stage-Dependent Role of Eicosanoids in Colorectal Cancer

Key Points

Study Design

PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Stage-Dependent Role of Eicosanoids in Colorectal Cancer

Key Points

Study Design

PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading